Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis

Junaid Abdulghani, Joshua E. Allen, David T. Dicker, Yingqiu Yvette Liu, David Goldenberg, Charles D. Smith, Robin Humphreys, Wafik S. El-Deiry

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Fingerprint Dive into the research topics of 'Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis'. Together they form a unique fingerprint.

Agriculture & Biology

Chemical Compounds

Medicine & Life Sciences